Engager

For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional…

100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108…

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely…

Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy moleculesANKET is first NK cell engager technology to engage NKp46, CD16, IL-2 variant…